RenovoRx logo
RenovoRx
RNXT | NASDAQ
Chart Builder DCF Calculator
$0.94
-$0.10 (-9.62%)
At close: Nov 16, 2026, 3:59 PM ET
$0.97
+$0.03 (+3.61%)
After-hours: Nov 16, 2026, 7:58 PM ET

RenovoRx Company Profile

Company profile explained

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.

Key Executives

Name Position
Shaun R. Bagai Chief Executive Officer, Secretary & Director
Leesa Gentry Chief Clinical Officer
Mark Voll CFO & Principal Accounting Officer
Phil Stocton Vice President of Sales & Market Development
Ramtin Agah Founder, Executive Chairman & Chief Medical Officer
Ronald Kocak VP of Finance & Controller
Tom Kelly Vice President of Quality & Operations

Latest SEC Filings

Date Type Title
Oct 16, 2026 RW Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 15, 2026 4 Filing
Aug 20, 2026 8-K Current Report
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K/A [Amend] Current Report
Aug 12, 2026 8-K Current Report
View All SEC Filings ➞
RenovoRx
RenovoRx logo
Country United States
IPO Date Aug 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Shaun R. Bagai

Contact Details

4546 El Camino Real Mountain View, California 94040 United States

Stock Details

Ticker Symbol RNXT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574094
CUSIP Number 75989R107
ISIN Number US75989R1077
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.